LYMPHOCYTE SUBSET DISTRIBUTION AFTER COMBINED CHEMO- AND RADIOTHERAPY IN PATIENTS WITH CANCER OF THE ORAL CAVITY, OROPHARYNX, AND LARYNGOPHARYNX

Authors

  • M. Vorobyov Municipal Non-Profit Enterprise «Zaporizhzhia Regional Antitumor Center» Zaporizhzhia Regional Council, Zaporizhzhia, Ukraine
  • L. Zvarych State Institution «National Research Center for Radiation Medicine, Hematology and Oncology of The National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine
  • D. Bazyka State Institution «National Research Center for Radiation Medicine, Hematology and Oncology of The National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine

DOI:

https://doi.org/10.15407/exp-oncology.2025.02.207

Keywords:

lymphocytes, oral cancer, prognosis, immune system, biomarkers

Abstract

Aim. To study the prognostic value of the lymphocyte subset distribution to predict the overall survival and its association with the clinicopathologic characteristics and treatment in patients with cancer of the oral cavity, oropharynx, and laryngopharynx. Materials and Methods. 44 patients were examined. Immunophenotyping of lymphocyte subsets was performed in peripheral blood samples using flow cytometry. The lymphocyte subset distribution was analyzed depending on the clinicopathological characteristics and treatment outcome, as well as the overall survival. Results. The changes in CD3+ T-cells and CD3+57+ NKT counts were associated with the sex of the patients, TCRαβ+ T-cells — with the stage of the disease, CD4+8+T-cells and CD3-16+57+ NK — with the tumor size and differentiation grade, and CD3+HLA-DR+,CD8+ T-cells, and CD4+/CD8+ ratio — with lymph node involvement. The content of CD3+HLA-DR+ and TCRαβ+ T-cells, CD3-16+57+ NK, and CD3+57+ NKT differed in patients depending on the tumor location. There were changes in CD19+ and HLA-DR+ B-cells, CD3+, CD4+, CD4+25+ and TCRαβ+ T-cells, CD3-CD16+57+ NK, and CD3+57+ NKT during treatment, with the most pronounced changes after the first stage of RT. The relative number of CD3+HLA-DR+ and tumor size T4 influenced the overall survival of patients ((HR = 0.798, 95% CI, 0.658—0.967, p = 0.021) and (HR = 3.015, 95% CI, 1.303—6.975, p = 0.009), respectively). Conclusion. Parameters of lymphocyte subsets can be promising prognostic markers.

References

Bouvard V, Nethan ST, Singh D, et al. IARC perspective on oral cancer prevention. N Engl J Med. 2022;387(21):1999- 2005. https://doi.org/10.1056/nejmsr2210097

Huang J, Chan SC, Ko S, et al. Disease burden, risk factors, and trends of lip, oral cavity, pharyngeal cancers: A global analysis. Cancer Med. 2023;12(17):18153-18164. https://doi.org/10.1002/cam4.6391

Rybachuk AV, Tolstanov OK, Malanchuk VO, et al. Analysis of morbidity and mortality of patients with malignant neoplasms of the lip and oral cavity in Ukraine. World Med Biol. 2022;18(80):134. https://doi.org/10.26724/2079- 8334-2022-2-80-134-140

Fedorenko ZP, Goulak LO, Gorokh YL, et al. Cancer in Ukraine 2021–2022. Incidence, mortality, prevalence and other relevant statistics. Bulletin of the National Cancer Registry of Ukraine. 2023;24:82

Grafton-Clarke C, Chen KW, Wilcock J. Diagnosis and referral delays in primary care for oral squamous cell can- cer: a systematic review. Br J Gen Pract. 2019;69(679):e112-126. https://doi.org/10.3399/bjgp18x700205

Iida M, Takayama E, Naganawa K, et al. Increase of peripheral blood CD57+ T-cells in patients with oral squamous cell carcinoma. Anticancer Res. 2014;34(10):5729-5734.

Shan Z, Liu S, Yang L, et al. Repertoire of peripheral T cells in patients with oral squamous cell carcinoma. Oral Dis. 2020;26(5):885-893. https://doi.org/10.1111/odi.13311

Feng L, Li T-K, Yin K, etal. Effectofpembrolizumabon Tlymphocytesubsetsinpatientswithadvancedoralcancerand its therapeutic effect. Medicine (Baltimore). 2022;101(36):e30534. https://doi.org/10.1097/md.0000000000030534

Hasegawa T, Iga T, Takeda D, et al. Neutrophil-lymphocyte ratio associated with poor prognosis in oral cancer: a retrospective study. BMC Cancer. 2020;20(1). https://doi.org/10.1186/s12885-020-07063-1

Lee JJ, Lin CL, Chen THH, et al. Changes in peripheral blood lymphocyte phenotypes distribution in patients with oral cancer/oral leukoplakia in Taiwan. Int J Oral Maxillofac Surg. 2010;39(8):806-814. https://doi.org/10.1016/j. ijom.2010.04.045

Chinn SB, Myers JN. Oral cavity carcinoma: Current management, controversies, and future directions. J Clin On- col. 2015;33(29):3269-3276. https://doi.org/10.1200/jco.2015.61.2929

Diao P, Wu Y, Ge H, et al. Preoperative circulating platelet, neutrophil, and lymphocyte counts predict survival in oral cancer. Oral Dis. 2019;25(4):1057-1066. https://doi.org/10.1111/odi.13049

Shen D-S, Yan C, Liang Y, et al. Prognostic significance of circulating lymphocyte subsets before treatment in patients with nasopharyngeal carcinoma. Cancer Manag Res. 2021;13:8109-8120. https://doi.org/10.2147/CMAR. S334094

Aggarwal S, Sharma SC, N.Das S. Dynamics of regulatory T cells (Tregs) in patients with oral squamous cell carci- noma. J Surg Oncol. 2017;116(8):1103-1113. https://doi.org/10.1002/jso.24782

Bin-Alee F, Arayataweegool A, Buranapraditkun S, et al. Evaluation of lymphocyte apoptosis in patients with oral cancer. J Appl Oral Sci. 2020;28. https://doi.org/10.1590/1678-7757-2020-0124

Wolf GT, Amendola BE, Diaz R, et al. Definite vs adjuvant radiotherapy: Comparative effects on lymphocyte subpop- ulations in patients with head and neck squamous carcinoma. Arch Otolaryngol Head Neck Surg. 1985;111(11):716- 726. https://doi.org/10.1001/archotol.1985.00800130048004

Wolf GT, Schmaltz S, Hudson J, et al. Alterations in T-lymphocyte subpopulations in patients with head and neck cancer: Correlations with prognosis. Arch Otolaryngol Head Neck Surg. 1987;113(11):1200-1206. https://doi. org/10.1001/archotol.1987.01860110066010

Yu T, Guo P, Wu Y, et al. The role of chemotherapy and operation on lymphocytes accumulation in peripheral blood obtained from patients with oral squamous cell carcinoma. Springerplus. 2015;4(1):698. https://doi.org/10.1186/ s40064-015-1485-6

Boucek J, Mrkvan T, Chovanec M, et al. Regulatory T cells and their prognostic value for patients with squa- mous cell carcinoma of the head and neck. J Cell Mol Med. 2010;14(1-2):426-433. https://doi.org/10.1111/j.1582- 4934.2008.00650.x

Grimm M, Feyen O, Hofmann H, et al. Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue. Tumour Biol. 2016;37(3):3807-3816. https://doi.org/10.1007/s13277- 015-4224-2

Lozac’h P, Corbeau P, Zabbe C, et al. Peripheral blood and tumor-infiltrating mononuclear cell analysis in esophagus and head and neck cancer. Med Oncol Tumor Pharmacother. 1987;4(1):7-10. https://doi.org/10.1007/bf02934928

Böttcher A, Ostwald J, Guder E, et al. Distribution of circulating natural killer cells and T lymphocytes in head and neck squamous cell carcinoma. Auris Nasus Larynx. 2013;40(2):216-221. https://doi.org/10.1016/j.anl.2012.07.004

Bas M, Bier H, Schirlau K, et al. Gamma–delta T-cells in patients with squamous cell carcinoma of the head and neck. Oral Oncol. 2006;42(7):691-697. https://doi.org/10.1016/j.oraloncology.2005.11.008

Balázs K, Kis E, Badie C, et al. Radiotherapy-induced changes in the systemic immune and inflammation parameters of head and neck cancer patients. Cancers (Basel). 2019;11(9):1324. https://doi.org/10.3390/cancers11091324

Verastegui EL, Morales RB, Barrera-Franco JL, et al. Long-term immune dysfunction after radiotherapy to the head and neck area. Int Immunopharmacol. 2003;3(8):1093-1104. https://doi.org/10.1016/s1567-5769(03)00013-4

Niu M, Combs SE, Linge A, et al. Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiat Oncol. 2021;16(1):141. https://doi.org/10.1186/s13014-021-01868-5

Dovšak T, Ihan A, Didanovič V, et al. Effect of surgery and radiotherapy on complete blood count, lymphocyte subsets and inflammatory response in patients with advanced oral cancer. BMC Cancer. 2018;18(1):235. https:// doi.org/10.1186/s12885-018-4136-9

Turner RJ, Guy TV, Geraghty NJ, et al. Low pretreatment CD4+:CD8+ T cell ratios and CD39+CD73+CD19+ B cell proportions are associated with improved relapse-free survival in head and neck squamous cell carcinoma. Int J Mol Sci. 2023;24(16):12538. https://doi.org/10.3390/ijms241612538

Dewyer NA, Wolf GT, Light E, et al. Circulating CD4‐positive lymphocyte levels as predictor of response to induc- tion chemotherapy in patients with advanced laryngeal cancer. Head Neck. 2014;36(1):9-14. https://doi.org/10.1002/ hed.23263

Beschel LM, Leu M, Reichardt SD, et al. T cell abundance in blood predicts acute organ toxicity in chemoradio- therapy for head and neck cancer. Oncotarget. 2016;7(40):65902-65915. https://doi.org/10.18632/oncotarget.11677

Downloads

Published

07.10.2025

How to Cite

Vorobyov, M., Zvarych, L., & Bazyka, D. (2025). LYMPHOCYTE SUBSET DISTRIBUTION AFTER COMBINED CHEMO- AND RADIOTHERAPY IN PATIENTS WITH CANCER OF THE ORAL CAVITY, OROPHARYNX, AND LARYNGOPHARYNX. Experimental Oncology, 47(2), 207–215. https://doi.org/10.15407/exp-oncology.2025.02.207

Issue

Section

Original contributions